NCT07006506View on ClinicalTrials.gov

A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant

PHASE2RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

May 21, 2025

Primary Completion Date

May 21, 2029

Study Completion Date

May 21, 2029

Conditions
Graft Versus Host DiseaseGraft Vs Host DiseaseHematologic Malignancy
Interventions
DRUG

Belumosudil

Belumosudil is an oral selective inhibitor of Rho-GTPase-associated coiled-coil kinase 2 (ROCK2)

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activites), Rockville Centre

11725

RECRUITING

Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity), Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER